EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)

Jae Hee Cheon iD, Hyun-Soo Kim iD, Dong Soo Han iD, Sung Kook Kim iD, Sung Jae Shin iD, Joo Sung Kim iD, Byong Duk Ye iD, Geun Am Song iD, YoungJa Lee iD, Youngdoe Kim iD, Yoosun Lee iD, Won Ho Kim iD und 1 weitere

Gut and Liver · 15.09.2023 · 17 (5) · 777-785

DOI: 10.5009/gnl220278 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Gut and Liver, online erschienen am 29.12.2022. Verfasst von Jae Hee Cheon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Behcet Syndrome, Intestinal Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Korea Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: To date, there is no prospective study that specifically investigated the efficacy of infliximab in intestinal Behçet's disease (BD). This study evaluated the efficacy of infliximab in patients with moderate-to-severe active intestinal BD that are refractory to conventional therapies.

Methods

This phase 3, interventional, open-label, single-arm study evaluated clinical outcomes of infliximab treatment in patients with moderate-to-severe intestinal BD. The coprimary endpoints were clinical response, decrease in disease activity index for intestinal BD (DAIBD) score ≥20 from weeks 0 to 8 for the induction therapy and week 32 for the maintenance therapy.

Results

A total of 33 patients entered the induction therapy and were treated with infliximab 5 mg/kg intravenously at weeks 0, 2, and 6. The mean DAIBD score changed from 90.8±40.1 at week 0 to 40.3±36.4 at week 8, with a significant mean change of 50.5±36.4 (95% confidence interval, 37.5 to 63.4; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeIntestinal DiseasesHumansInfliximabIntestinesProspective StudiesTreatment Outcome

Stichwörter der Autor:innen

Behcet syndromeClinical efficacyInfliximabIntestinal diseasesTumor necrosis factor-alpha

Substanzen

Infliximab

Autor:innen und Institutionen

  • Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
  • Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
  • Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea.
  • Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

ORCID-Profile: Jae Hee Cheon, Hyun-Soo Kim, Dong Soo Han, Sung Kook Kim, Sung Jae Shin, Joo Sung Kim, Byong Duk Ye, Geun Am Song, YoungJa Lee, Youngdoe Kim, Yoosun Lee, Won Ho Kim

Förderung

  • Janssen Korea Ltd

Zitieren

APA

Cheon, J. H., Kim, H. S., Han, D. S., Kim, S. K., Shin, S. J., Kim, J. S., Ye, B. D., Song, G. A., Lee, Y., Kim, Y., Lee, Y., Kim, W. H., & BEGIN Study Group (2023). Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN). Gut and Liver, 17(5), 777-785. https://doi.org/10.5009/gnl220278

Vancouver

Cheon JH, Kim HS, Han DS, Kim SK, Shin SJ, Kim JS, et al. Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN). Gut and Liver. 2023;17(5):777-785. doi:10.5009/gnl220278

BibTeX
@article{Cheon2023,
  author = {Cheon, Jae Hee and Kim, Hyun-Soo and Han, Dong Soo and Kim, Sung Kook and Shin, Sung Jae and Kim, Joo Sung and Ye, Byong Duk and Song, Geun Am and Lee, YoungJa and Kim, Youngdoe and Lee, Yoosun and Kim, Won Ho and BEGIN Study Group, BEGIN Study Group},
  title = {Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)},
  journal = {Gut and Liver},
  year = {2023},
  volume = {17},
  number = {5},
  pages = {777--785},
  doi = {10.5009/gnl220278}
}
Kostenlos starten →